Hepatitis B viral assembly effectors
US10273228B2 · kind B2 · utility
0Cited by
2References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 15, 2016 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Apr 15, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.